| Methods |
Randomized trial comparing 5‐aminosalicylic acid and SASP |
| Participants |
Adult patients with ulcerative colitis of at least two years duration with mild to moderate relapse (N = 86) |
| Interventions |
2.4 g/day 5‐ASA (n = 44) or 3 g/day SASP (n = 42) for 6 weeks |
| Outcomes |
Clinical improvement, endoscopic and histologic appearance, indexes of phlogosis, haematic crasis, hepatic and renal functionality, and adverse events |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No drop‐outs were reported |
| Selective reporting (reporting bias) |
Low risk |
Expected outcomes were reported |
| Other bias |
Low risk |
The study appears to be free of other sources of bias |
